The Latest in News

FDA grants priority review to CAR T-cell therapy for DLBCL

January 17, 2018

Aggressive Lymphomas

AUDIO: Immunotherapy’s role in NHL

January 11, 2018

VcR-CVAD yields high responses, ‘excellent’ survival in MCL

January 11, 2018

Aggressive Lymphomas

Study identifies predictors of acquired von Willebrand disease

December 26, 2017

Indolent Lymphoma

Rare neurological complication linked to Waldenstrom disease

December 18, 2017

Indolent Lymphoma

Rituximab may be best choice for splenic MZL

December 18, 2017

Indolent Lymphoma

VIDEO - New lymphoma drug approvals: Clinical use, future directions

December 14, 2017

Aggressive Lymphomas

VIDEO: Ibrutinib PFS is nearly 3 years in MCL patients who had one prior therapy

December 13, 2017

Aggressive Lymphomas

VTE rates in lenalidomide-treated NHL may warrant prophylaxis

December 12, 2017

Aggressive Lymphomas

VIDEO: Venetoclax/rituximab prolongs PFS in relapsed/refractory CLL

December 12, 2017

Aggressive Lymphomas

VIDEO: CAR T cell axi-cel drives B-cell lymphomas into remission

December 11, 2017

Aggressive Lymphomas

Three-month response to CAR T-cells looks durable in DLBCL

December 11, 2017

Aggressive Lymphomas

MAVORIC: Mogamulizumab tops vorinostat in pretreated CTCL

December 10, 2017

Aggressive Lymphomas

Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas

December 10, 2017

Marginal zone lymphoma treatment studies to be presented at ASH

November 27, 2017

Indolent Lymphoma